Strand Siri H, Hoyer Soren, Lynnerup Anne-Sofie, Haldrup Christa, Storebjerg Tine Maj, Borre Michael, Orntoft Torben F, Sorensen Karina D
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Department of Histopathology, Aarhus University Hospital, Aarhus, Denmark.
Clin Epigenetics. 2015 Oct 15;7:111. doi: 10.1186/s13148-015-0146-5. eCollection 2015.
Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological features cannot clearly distinguish aggressive from indolent tumors at the time of diagnosis; thus, new prognostic biomarkers are urgently needed. The DNA methylation variant 5-hydroxymethylcytosine (5hmC, an oxidized derivative of 5-methylcytosine) has recently emerged as a new diagnostic and/or prognostic biomarker candidate for several human malignancies. However, this remains to be systematically investigated for PC. In this study, we determined 5hmC levels in 311 PC (stratified by ERG status) and 228 adjacent non-malignant (NM) prostate tissue specimens by immunohistochemical analysis of a tissue microarray, representing a large radical prostatectomy (RP) cohort with long clinical follow-up. We investigated possible correlations between 5hmC and routine clinicopathological variables and assessed the prognostic potential of 5hmC by Kaplan-Meier and uni- and multivariate Cox regression analyses in ERG+ (n = 178) vs. ERG- (n = 133) PCs using biochemical recurrence (BCR) as endpoint.
We observed a borderline significant (p = 0.06) reduction in 5hmC levels in PC compared to NM tissue samples, which was explained by a highly significant (p < 0.001) loss of 5hmC in ERG- PCs. ERG status was not predictive of BCR in this cohort (p = 0.73), and no significant association was found between BCR and 5hmC levels in ERG+ PCs (p = 0.98). In contrast, high 5hmC immunoreactivity was a significant adverse predictor of BCR after RP in ERG- PCs, independent of Gleason score, pathological tumor stage, surgical margin status, and pre-operative prostate-specific antigen (PSA) level (hazard ratio (HR) (95 % confidence interval (CI)): 1.62 (1.15-2.28), p = 0.006).
This is the first study to demonstrate a prognostic potential for 5hmC in PC. Our findings highlight the importance of ERG stratification in PC biomarker studies and suggest that epigenetic mechanisms involving 5hmC are important for the development and/or progression of ERG- PC.
前列腺癌(PC)可根据TMPRSS2-ERG基因融合状态分为不同的分子亚型,但其潜在的预后价值仍存在争议。同样,常规临床病理特征在诊断时无法明确区分侵袭性肿瘤和惰性肿瘤;因此,迫切需要新的预后生物标志物。DNA甲基化变体5-羟甲基胞嘧啶(5hmC,5-甲基胞嘧啶的氧化衍生物)最近已成为几种人类恶性肿瘤新的诊断和/或预后生物标志物候选物。然而,对于PC,这仍有待系统研究。在本研究中,我们通过对组织微阵列进行免疫组化分析,测定了311例PC(按ERG状态分层)和228例相邻非恶性(NM)前列腺组织标本中的5hmC水平,该组织微阵列代表了一个具有长期临床随访的大型前列腺癌根治术(RP)队列。我们研究了5hmC与常规临床病理变量之间的可能相关性,并以生化复发(BCR)为终点,通过Kaplan-Meier以及单因素和多因素Cox回归分析,评估了ERG阳性(n = 178)与ERG阴性(n = 133)PC中5hmC的预后潜力。
与NM组织样本相比,我们观察到PC中5hmC水平有临界显著降低(p = 0.06),这可以通过ERG阴性PC中5hmC的高度显著降低(p < 0.001)来解释。在该队列中,ERG状态不能预测BCR(p = 0.73),并且在ERG阳性PC中未发现BCR与5hmC水平之间有显著关联(p = 0.98)。相比之下,在ERG阴性PC中,高5hmC免疫反应性是RP后BCR的显著不良预测因子,与Gleason评分、病理肿瘤分期、手术切缘状态和术前前列腺特异性抗原(PSA)水平无关(风险比(HR)(95%置信区间(CI)):1.62(1.15 - 2.28),p = 0.006)。
这是第一项证明5hmC在PC中具有预后潜力的研究。我们的发现突出了ERG分层在PC生物标志物研究中的重要性,并表明涉及5hmC的表观遗传机制对ERG阴性PC的发生和/或进展很重要。